Inhibition of the soluble epoxide hydrolase attenuates monocrotaline- induced pulmonary hypertension in rats

Journal of Hypertension

Volumn 27, Issue 2, 2009, Pages 322-331

  Revermann, Marc ^a,b   Barbosa Sicard, Eduardo ^a   Dony, Eva ^c   Schermuly, Ralph T ^d   Morisseau, Christophe ^e   Geisslinger, Gerd ^b   Fleming, Ingrid ^a   Hammock, Bruce D ^d   Brandes, Ralf P ^a,f  

^a GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f GOETHE UNIVERSITY   (Germany)

Author keywords

Epoxyeicosatrienoic acids; Lipid mediators; Monocrotaline

Indexed keywords

1,2 (3 ADAMANTAN 1 YL UREIDO)DODECANOIC ACID; 4 [4 (3 ADAMANTAN 1 YL UREIDO)CYCLOHEXYLOXY]BENZOIC ACID; BENZOIC ACID DERIVATIVE; BROXURIDINE; CYTOCHROME P450; CYTOCHROME P450 EPOXYGENASE; EPOXIDE HYDROLASE; EPOXIDE HYDROLASE INHIBITOR; EPOXYICOSATRIENOIC ACID; LAURIC ACID; MONOCROTALINE; UNCLASSIFIED DRUG; DIHOMO GAMMA LINOLENIC ACID; DRUG DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL WALL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MODEL; ENDOTHELIUM CELL; ENZYME INHIBITION; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; PATHOLOGY; WISTAR KYOTO RAT;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; EPOXIDE HYDROLASES; HYPERTENSION, PULMONARY; MALE; MONOCROTALINE; PULMONARY ARTERY; RATS; RATS, INBRED WKY;

EID: 63849131965     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32831aedfa     Document Type: Article

References (32)

1. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43:5S-12S.
2. Ghofrani HA, Voswinckel R, Reichenberger F, Weissmann N, Schermuly RT, Seeger W, Grimminger F. Hypoxia- and nonhypoxia-related pulmonary hypertension - established and new therapies. Cardiovasc Res 2006; 72:30-40.
3. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351:1655-1665.
4. Pokreisz P, Fleming I, Kiss L, Barbosa-Sicard E, Fisslthaler B, Falck JR, et al. Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling. Hypertension 2006; 47:762-770.
5. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, Busse R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999; 401:493-497.
6. Michaelis UR, Fisslthaler B, Barbosa-Sicard E, Falck JR, Fleming I, Busse R. Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxiainduced endothelial cell migration and angiogenesis. J Cell Sci 2005; 118:5489-5498.
7. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999; 285:1276-1279.
8. Fleming I. Cytochrome p450 and vascular homeostasis. Circ Res 2001; 89:753-762.
9. Inceoglu B, Schmelzer KR, Morisseau C, Jinks SL, Hammock BD. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat 2007; 82:42-49.
10. Jung O, Brandes RP, Kim IH, Schweda F, Schmidt R, Hammock BD, et al. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 2005; 45:759-765.
11. Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai HJ, et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A 2006; 103:18733-18738.
12. Schmelzer KR, Inceoglu B, Kubala L, Kim IH, Jinks SL, Eiserich JP, Hammock BD. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A 2006; 103:13646-13651.
13. Schultze AE, Roth RA. Chronic pulmonary hypertension - the monocrotaline model and involvement of the hemostatic system. J Toxicol Environ Health B Crit Rev 1998; 1:271-346.
14. Hwang SH, Tsai HJ, Liu JY, Morisseau C, Hammock BD. Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem 2007; 50:3825- 3840.
15. Morisseau C, Goodrow MH, Newman JW, Wheelock CE, Dowdy DL, Hammock BD. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol 2002; 63:1599- 1608.
16. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Samidurai A, Pullamsetti S, Weissmann N, et al. Antiremodeling effects of iloprost and the dualselective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res 2004; 94:1101-1108.
17. Barbosa-Sicard E, Markovic M, Honeck H, Christ B, Muller DN, Schunck WH. Eicosapentaenoic acid metabolism by cytochrome P450 enzymes of the CYP2C subfamily. Biochem Biophys Res Commun 2005; 329:1275- 1281.
18. Muller DN, Schmidt C, Barbosa-Sicard E, Wellner M, Gross V, Hercule H, et al. Mouse Cyp4a isoforms: enzymatic properties, gender- and strainspecific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation. Biochem J 2007; 403:109-118.
19. Dhanasekaran A, Al-Saghir R, Lopez B, Zhu D, Gutterman DD, Jacobs ER, Medhora M. Protective effects of epoxyeicosatrienoic acids on human endothelial cells from the pulmonary and coronary vasculature. Am J Physiol Heart Circ Physiol 2006; 291:H517-H531.
20. Yang S, Lin L, Chen JX, Lee CR, Seubert JM, Wang Y, et al. Cytochrome P- 450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-alpha via MAPK and PI3K/Akt signaling pathways. Am J Physiol Heart Circ Physiol 2007; 293:H142-H151.
21. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003; 22:358-363.
22. Thomas HC, Lame MW, Dunston SK, Segall HJ, Wilson DW. Monocrotaline pyrrole induces apoptosis in pulmonary artery endothelial cells. Toxicol Appl Pharmacol 1998; 151:236-244.
23. McMurtry MS, Moudgil R, Hashimoto K, Bonnet S, Michelakis ED, Archer SL. Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2007; 292:L872-L878.
24. Fang X, Moore SA, Stoll LL, Rich G, Kaduce TL, Weintraub NL, Spector AA. 14,15-Epoxyeicosatrienoic acid inhibits prostaglandin E2 production in vascular smooth muscle cells. Am J Physiol 1998; 275:H2113-H2121.
25. Sun J, Sui X, Bradbury JA, Zeldin DC, Conte MS, Liao JK. Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenasederived eicosanoids. Circ Res 2002; 90:1020-1027.
26. Sawada H, Mitani Y, Maruyama J, Jiang BH, Ikeyama Y, Dida FA, et al. A nuclear factor-kappaB inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary hypertension in rats. Chest 2007; 132:1265-1274.
27. Zhu D, Bousamra M, Zeldin DC, Falck JR, Townsley M, Harder DR, et al. Epoxyeicosatrienoic acids constrict isolated pressurized rabbit pulmonary arteries. Am J Physiol Lung Cell Mol Physiol 2000; 278:L335-L343.
28. Carroll MA, Balazy M, Margiotta P, Falck JR, McGiff JC. Renal vasodilator activity of 5,6-epoxyeicosatrienoic acid depends upon conversion by cyclooxygenase and release of prostaglandins. J Biol Chem 1993; 268:12260-12266.
29. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 2001; 276:36059-36062.
30. Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, Hammock BD. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci U S A 2005; 102:9772-9777.
31. Ishizaki T, Shigemori K, Nakai T, Miyabo S, Ozawa T, Chang SW, Voelkel NF. Leukotoxin, 9,10-epoxy-12-octadecenoate causes edematous lung injury via activation of vascular nitric oxide synthase. Am J Physiol 1995; 269:L65-L70.
32. Moghaddam MF, Grant DF, Cheek JM, Greene JF, Williamson KC, Hammock BD. Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase. Nat Med 1997; 3:562-566.